ThinkPanmure Initiates Coverage on Achillon (ACHN) with a Buy
More News related to ACHN
- Achillion Pharmaceuticals (ACHN) Receives Non-Compliance Notification From NASDAQ
- Achillion Pharma (ACHN) Receives Notice from NASDAQ Regarding Stockholders' Equity Requirements
- Achillion Receives Notice From NASDAQ
- Achillion Reports Third Quarter Results
- Achillion to Present at Three Upcoming Conferences
More News related to New Coverage
- Credit Suisse Restarts Coverage on MEMC Electronic Materials (WFR) with a Neutral
- Natixis Bleichroeder Initiates Coverage on AGA Medical (AGAM) with a Buy
- Leerink Swann Resumes Coverage on Medivation (MDVN) with an Outperform
- J.P. Morgan Initiates Coverage on Liberty Global (LBTYA) with a Neutral
- Wells Fargo Initiates Coverage on AGA Medical Holdings (AGAM) with a Market Perform
ThinkPanmure initiates coverage on Achillon (Nasdaq: ACHN) with a Buy. Price target $2.50.
Achillion Pharmaceuticals, Inc. (Achillion) is a biopharmaceutical company focused on the discovery, development and commercialization of treatments for infectious diseases.
Related Categories
New CoverageStocks Mentioned
+0.00Related Entities
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
